85803-43-6

Usage

Uses

Used in Pharmaceutical Industry:
S-Benzyl-L-cysteinol is used as a chiral building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Cosmetic and Personal Care Industry:
S-Benzyl-L-cysteinol is used as an ingredient in cosmetic and personal care products, leveraging its antioxidant properties to protect against oxidative stress and promote skin health.
Used in Food Industry:
S-Benzyl-L-cysteinol is used as a flavoring agent in food products, enhancing the taste and aroma of various culinary creations.
Used in Chemical Synthesis:
S-Benzyl-L-cysteinol is used as a chiral auxiliary in asymmetric synthesis reactions, facilitating the production of enantiomerically pure compounds for various applications.
Used in Antioxidant Applications:
S-Benzyl-L-cysteinol is used as an antioxidant to combat oxidative stress, potentially serving as a therapeutic agent for treating oxidative stress-related diseases.

InChI:InChI=1/C10H15NOS/c11-10(6-12)8-13-7-9-4-2-1-3-5-9/h1-5,10,12H,6-8,11H2/t10-/m0/s1

Upstream product

• 52844-67-4 S-benzyl-L-cysteine ethyl ester hydrochloride 
• 22728-88-7 S-benzylcysteine methyl ester 
• 3054-01-1 S-benzyl-L-cysteine 
• 953-18-4 S-benzyl-L-cysteine ethyl ester 

Downstream Products

• 111904-35-9 (1'R)-2-fluoro-N-<1-(hydroxymethyl)-2-(benzylthio)-ethyl>benzamide 
• 185146-21-8 (R)-1-Benzylsulfanylmethyl-2-(tert-butyl-dimethyl-silanyloxy)-ethylamine 
• 139428-96-9 N-tert-butoxycarbonyl-S-benzyl-(R)-cysteinol 
• 916347-78-9 (2S,4R)-4-[(benzylthio)methyl]-2-(4-fluorophenyl)-2-(trifluoromethyl)-1,3-oxazolidine 
• 916347-56-3 (2R,4R)-4-[(benzylthio)methyl]-2-(4-fluorophenyl)-2-(trifluoromethyl)-1,3-oxazolidine 
• 916347-57-4 (2R)-3-(benzylthio)-2-{[(1R)-3-cyclopropyl-1-(4-fluorophenyl)-1-(trifluoromethyl)prop-2-yn-1-yl]amino}propan-1-ol 
• 916347-58-5 3-(benzylsulfonyl)-N-[(1R)-3-cyclopropyl-1-(4-fluorophenyl)-1-(trifluoromethyl)prop-2-yn-1-yl]-L-alanine 

Relevant academic research and scientific papers

TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS

Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Aldehyde derivatives and their use as calpain inhibitors

Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II): wherein R1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of-X-R3 in which X represents O,-S(O)m-(m = 0, 1, or 2), and R3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R?-Y-or R?O-CH(R?)-in which Y represents a 3-to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R? represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R? represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R? represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5. wherein R?, R?, R?, and R1? are defined in the specification.

Use of Liquid Crystal Induced Circular Dichroism for Absolute Configurational Assignments of β-Amino Alcohols

Dissolution of small quantities of chiral β-amino alcohols in liquid crystalline N-(p-methoxybenzylidene)-p-n-butylaniline (MBBA) results in induced rotations due to the formation of a cholesteric (chiral) liquid crystal phase.The induced rotations are several orders of magnitude larger than those observed for β-amino alcohols in isotropic solutions, and the signs of these rotations can be correlated with the absolute configurations of the chiral amino alcohols when standard conformational analysis arguments and the preference of elongated molecules to align with MBBA are considered.

Pyrimidinylpropenamides as antitumor agents. Analogues of the antibiotic sparsomycin

A series of pyrimidinylpropenamides 9 and their oxidation products 10 was prepared, as analogues of sparsomycin (1), for antitumor evaluation. Syntheses involved condensation of the appropriate amino alcohol 5 with acid 8. The resulting sulfides 9 were then oxidized with NaIO4 or H2O2 to sulfoxides 10. Activity was studied in lymphocytic leukemia P-388 and KB cell culture. With the exception of the n-decyl analogue, all of the deoxygenated compounds 9 were inactive regardless of the sterochemical form. In the sulfoxide series 10, those compounds prepared with an L configuration at the asymmetric carbon were also inactive. The completely racemic sulfoxides, on the other hand, displayed substantial antitumor activity (ILS=37-61% in P-388; ED50=1.2-2.4μg/ml in KB) suggesting that both the presence of a sulfoxide moiety and a D configuration at the chiral carbon atom were structural requirements for a positive antitumor response. There appeared to be a large tolerance for the group substituted at the sulfoxide moiety, however.